<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="pmcid: 7026129 doi: 10.3389/fmicb.2020.00150 : Microbiology: Review Antiviral Drugs Against" exact="Severe" post="Fever With Thrombocytopenia Syndrome Virus Infection Takayama-ItoMutsuyoSaijoMasayuki*[], Department of"/>
 <result pre="7026129 doi: 10.3389/fmicb.2020.00150 : Microbiology: Review Antiviral Drugs Against Severe" exact="Fever" post="With Thrombocytopenia Syndrome Virus Infection Takayama-ItoMutsuyoSaijoMasayuki*[], Department of Virology"/>
 <result pre="10.3389/fmicb.2020.00150 : Microbiology: Review Antiviral Drugs Against Severe Fever With" exact="Thrombocytopenia" post="Syndrome Virus Infection Takayama-ItoMutsuyoSaijoMasayuki*[], Department of Virology I, National"/>
 <result pre=": Microbiology: Review Antiviral Drugs Against Severe Fever With Thrombocytopenia" exact="Syndrome" post="Virus Infection Takayama-ItoMutsuyoSaijoMasayuki*[], Department of Virology I, National Institute"/>
 <result pre="Review Antiviral Drugs Against Severe Fever With Thrombocytopenia Syndrome Virus" exact="Infection" post="Takayama-ItoMutsuyoSaijoMasayuki*[], Department of Virology I, National Institute of Infectious"/>
 <result pre="Virus Infection Takayama-ItoMutsuyoSaijoMasayuki*[], Department of Virology I, National Institute of" exact="Infectious" post="DiseasesTokyoJapan Edited by: Lijun Rong, The University of Illinois"/>
 <result pre="is permitted which does not comply with these terms. Abstract" exact="Severe" post="fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne"/>
 <result pre="does not comply with these terms. Abstract Severe fever with" exact="thrombocytopenia" post="syndrome (SFTS) is an emerging tick-borne infectious disease caused"/>
 <result pre="not comply with these terms. Abstract Severe fever with thrombocytopenia" exact="syndrome" post="(SFTS) is an emerging tick-borne infectious disease caused by"/>
 <result pre="Abstract Severe fever with thrombocytopenia syndrome (SFTS) is an emerging" exact="tick-borne" post="infectious disease caused by SFTS virus (SFTSV), which is"/>
 <result pre="Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne" exact="infectious disease" post="caused by SFTS virus (SFTSV), which is a novel"/>
 <result pre="fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne infectious" exact="disease" post="caused by SFTS virus (SFTSV), which is a novel"/>
 <result pre="candidates. While animal experiments and retrospective studies have demonstrated the" exact="limited" post="efficacy of ribavirin, it was also speculated that ribavirin"/>
 <result pre="speculated that ribavirin would be effective in patients with a" exact="viral" post="load &amp;lt;1 × 106 copies/mL. Favipiravir showed higher efficacy"/>
 <result pre="recent advances in antiviral drugs against SFTSV. severe fever with" exact="thrombocytopenia" post="syndrome severe fever with thrombocytopenia syndrome virus antiviral ribavirin"/>
 <result pre="advances in antiviral drugs against SFTSV. severe fever with thrombocytopenia" exact="syndrome" post="severe fever with thrombocytopenia syndrome virus antiviral ribavirin favipiravir"/>
 <result pre="against SFTSV. severe fever with thrombocytopenia syndrome severe fever with" exact="thrombocytopenia" post="syndrome virus antiviral ribavirin favipiravir Funding Ministry of Health,"/>
 <result pre="SFTSV. severe fever with thrombocytopenia syndrome severe fever with thrombocytopenia" exact="syndrome" post="virus antiviral ribavirin favipiravir Funding Ministry of Health, Labour"/>
 <result pre="Research and Development10.13039/10000961916fk0108002j17fk0108202j18fk0108002j19fk0108072j19fk0108081j fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction" exact="Severe" post="fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne"/>
 <result pre="fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction Severe fever with" exact="thrombocytopenia" post="syndrome (SFTS) is an emerging tick-borne infectious disease caused"/>
 <result pre="table-count: equation-count: ref-count: page-count: word-count: Introduction Severe fever with thrombocytopenia" exact="syndrome" post="(SFTS) is an emerging tick-borne infectious disease caused by"/>
 <result pre="Introduction Severe fever with thrombocytopenia syndrome (SFTS) is an emerging" exact="tick-borne" post="infectious disease caused by SFTS virus (SFTSV), a novel"/>
 <result pre="Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne" exact="infectious disease" post="caused by SFTS virus (SFTSV), a novel bunyavirus classified"/>
 <result pre="fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne infectious" exact="disease" post="caused by SFTS virus (SFTSV), a novel bunyavirus classified"/>
 <result pre="and nonstructural proteins. The RdRp of SFTSV is responsible for" exact="viral" post="replication and is a major target of nucleoside analogs,"/>
 <result pre="leukocytopenia, and multiorgan dysfunction in Hubei and Henan provinces in" exact="Central" post="China (Yu et al., 2011). Subsequently, the virus was"/>
 <result pre="al., 2016). Although World Health Organization listed SFTS as a" exact="disease" post="requiring urgent research and development (World Health Organization, 2017),"/>
 <result pre="available effective SFTS treatment. The development of vaccines against SFTSV" exact="infection" post="has been attempted (Dong et al., 2019; Kwak et"/>
 <result pre="development of specific treatment for SFTS is crucial because SFTSV" exact="infection" post="is relatively rare and the affected patients are mainly"/>
 <result pre="antiviral drugs may potentially be effective in treatment of multiple" exact="viral" post="infections, testing approved drugs is considered as a reasonable"/>
 <result pre="of antiviral drugs in the treatment of SFTSV infections. However," exact="adult" post="mice and hamsters are not susceptible to SFTSV infection"/>
 <result pre="However, adult mice and hamsters are not susceptible to SFTSV" exact="infection" post="(Jin et al., 2012) and non-human primate models show"/>
 <result pre="et al., 2019) were found to be susceptible to SFTSV" exact="infection" post="following subcutaneous inoculation, and newborn mice and rats were"/>
 <result pre="inoculation, and newborn mice and rats were susceptible to SFTSV" exact="infection" post="when inoculated intracerebrally (Chen et al., 2012; Zivcec et"/>
 <result pre="103 TCID50 0 0.05 μg/animal (once) 0 *Non-lethal model. The" exact="viral" post="loads in spleen and serum were significantly reduced. **The"/>
 <result pre="PFU, plaque-forming unit; p.o., oral; s.c., subcutaneous; TCID, tissue culture" exact="infective" post="dose. In this review article, we summarize and discuss"/>
 <result pre="broad spectrum of antiviral activity against various viruses, such as" exact="respiratory" post="syncytial virus, influenza, measles, herpesvirus, human immunodeficiency virus, Lassa"/>
 <result pre="viruses, such as respiratory syncytial virus, influenza, measles, herpesvirus, human" exact="immunodeficiency" post="virus, Lassa virus, and [in combination with interferon (IFN)-α]"/>
 <result pre="immunodeficiency virus, Lassa virus, and [in combination with interferon (IFN)-α]" exact="hepatitis" post="C virus. Ribavirin can be administered orally, intravenously, or"/>
 <result pre="osteosarcoma-derived U2OS cells. When treated with ribavirin before and during" exact="infection" post="with SFTSV, the 99% inhibitory concentration (IC99) of ribavirin"/>
 <result pre="(Lee et al., 2017) (Table 1). Despite several differences in" exact="viral" post="strains and treatment procedure, ribavirin suppressed SFTS replication, suggesting"/>
 <result pre="inhibitory effects were observed, with reductions of &amp;gt;3 log10 in" exact="viral" post="titers. This study suggested that the combination of ribavirin"/>
 <result pre="useful in treating patients with SFTS. Ribavirin has shown a" exact="limited" post="protective effect in lethal SFTSV challenges in animal experiments"/>
 <result pre="ribavirin therapy, the platelet counts did not increase and the" exact="viral" post="loads did not decrease in comparison with those who"/>
 <result pre="unexpectedly observed that the patients who received ribavirin therapy had" exact="lower" post="platelet counts than those who did not. Another study"/>
 <result pre="6.25% (15/240 patients) to 1.16% (2/173 patients) in patients with" exact="viral" post="loads of &amp;lt;1 × 106 copies/mL (Li et al.,"/>
 <result pre="2018). However, no effect was observed among those with a" exact="viral" post="load of &amp;gt;1 × 106 copies/mL. Favipiravir Favipiravir (T-705),"/>
 <result pre="viruses, including the influenza virus, arenaviruses, bunyaviruses, West Nile virus," exact="yellow fever" post="virus, and foot-and-mouth disease virus (Furuta et al., 2009)."/>
 <result pre="arenaviruses, bunyaviruses, West Nile virus, yellow fever virus, and foot-and-mouth" exact="disease" post="virus (Furuta et al., 2009). Favipiravir is converted to"/>
 <result pre="to its active form, ribofuranosyl-5-triphosphate, by host enzymes and inhibits" exact="viral" post="RNA polymerase in the host cells. Only a few"/>
 <result pre="(22 μM) in Vero cells (Tani et al., 2016) was" exact="lower" post="than that of ribavirin (263 μM) (Shimojima et al.,"/>
 <result pre="or 100 mg/kg/day lost body weight and died from SFTSV" exact="infection" post="with reduction of the case fatality rate. All favipiravir-treated"/>
 <result pre="whereas the mice treated at 4 and 5 days post" exact="infection" post="exhibited 83% and 50% survival, respectively (Tani et al.,"/>
 <result pre="2016). Furthermore, treatment with favipiravir (300 or 150 mg/kg/day) provided" exact="complete" post="protection against a lethal SFTSV challenge in a STAT2"/>
 <result pre="120 and 200 mg/kg/day p.o. was investigated in a mouse" exact="infection" post="model, and all the mice survived when the treatment"/>
 <result pre="treatment was initiated at no later than 4 days post" exact="infection" post="(Tani et al., 2018). Hexachlorophene Yuan et al. (2019)"/>
 <result pre="C-mannosylation of thrombopoietin receptor (c-Mpl) for the treatment of immune" exact="thrombocytopenic purpura" post="and aplastic anemia (eltrombopag), and an antiprotozoal agent (broxyquinoline)."/>
 <result pre="of thrombopoietin receptor (c-Mpl) for the treatment of immune thrombocytopenic" exact="purpura" post="and aplastic anemia (eltrombopag), and an antiprotozoal agent (broxyquinoline)."/>
 <result pre="receptor (c-Mpl) for the treatment of immune thrombocytopenic purpura and" exact="aplastic anemia" post="(eltrombopag), and an antiprotozoal agent (broxyquinoline). Of them, hexachlorophene"/>
 <result pre="(c-Mpl) for the treatment of immune thrombocytopenic purpura and aplastic" exact="anemia" post="(eltrombopag), and an antiprotozoal agent (broxyquinoline). Of them, hexachlorophene"/>
 <result pre="highest selectivity index (50% cytotoxic concentration [CC50]/IC50, 18.7), which was" exact="lower" post="than that of the other four antiviral drugs identified"/>
 <result pre="et al., 2004). It was reported that hexachlorophene inhibited the" exact="viral" post="replication of severe acute respiratory syndrome-related coronavirus in vitro"/>
 <result pre="was reported that hexachlorophene inhibited the viral replication of severe" exact="acute" post="respiratory syndrome-related coronavirus in vitro by inhibiting 3C-like protease,"/>
 <result pre="reported that hexachlorophene inhibited the viral replication of severe acute" exact="respiratory" post="syndrome-related coronavirus in vitro by inhibiting 3C-like protease, which"/>
 <result pre="intracellular Ca2+ level and are widely used for treating various" exact="cardiovascular" post="diseases, including hypertension, angina, and supraventricular arrhythmias. Recently, the"/>
 <result pre="al., 2013), West Nile virus (Scherbik and Brinton, 2010), and" exact="Japanese encephalitis" post="virus (Wang et al., 2017) has been reported. Screening"/>
 <result pre="2013), West Nile virus (Scherbik and Brinton, 2010), and Japanese" exact="encephalitis" post="virus (Wang et al., 2017) has been reported. Screening"/>
 <result pre="phase (Li et al., 2019). This mechanism did not affect" exact="viral" post="binding, fusion, and budding. The results of in vitro"/>
 <result pre="mouse models (Table 2), revealing treatment effects of a reduced" exact="viral" post="load, increased platelet count, and decreased fatality rate in"/>
 <result pre="is one of the most widely used drugs for treating" exact="hypertension" post="and atherosclerosis in China. Thus, Li et al. (2019)"/>
 <result pre="of the most widely used drugs for treating hypertension and" exact="atherosclerosis" post="in China. Thus, Li et al. (2019) performed a"/>
 <result pre="also observed in the nifedipine-treated patients (2.4%) with a high" exact="viral" post="load (&amp;gt;106 copies/mL) when compared with the general SFTS"/>
 <result pre="(Bajramovic et al., 2004), Lassa virus (Welch et al., 2016)," exact="Crimean-Congo hemorrhagic fever" post="virus (Welch et al., 2017), influenza virus (Kumaki et"/>
 <result pre="such as La Crosse virus, Maporal virus, Punta Toro virus," exact="Rift Valley fever" post="virus, San Angelo virus, Heartland virus, and SFTSV. The"/>
 <result pre="an in vitro assay (Table 1). This value was much" exact="lower" post="than that of ribavirin (49.7 μM) in the same"/>
 <result pre="was more effective than 2′-FdC in controlling morbidity during the" exact="infection" post="(Smee et al., 2018). It was also found that"/>
 <result pre="100 mg/kg/day of either 2′-FdC or favipiravir significantly reduced the" exact="viral" post="titers in the serum. Furthermore, there was a slight"/>
 <result pre="treatment. It was speculated that this was caused by the" exact="limited" post="sample size (n = 4 or 5). Caffeic Acid"/>
 <result pre="exerts a variety of biological effects, including the suppression of" exact="cancer" post="cells (Tang et al., 2017; Bułdak et al., 2018)"/>
 <result pre="Thus, the authors speculated that CA mainly acted on the" exact="viral" post="particles or influenced the early stages of SFTSV infection,"/>
 <result pre="although it could act on the host cells to inhibit" exact="viral" post="genome replication. Amodiaquine Amodiaquine is a novel compound that"/>
 <result pre="al., 2017). The mechanism of inhibitory activity of amodiaquine against" exact="malaria" post="and those viruses remains unclear. Baba et al. (2017)"/>
 <result pre="&amp;gt;100 and 19.1 μM, respectively. The IC50 of amodiaquine was" exact="lower" post="than those of ribavirin (40.1 μM) and favipiravir (25.0"/>
 <result pre="favipiravir (25.0 μM). IFN-γ IFN-γ is the only member of" exact="type II" post="IFNs. It stimulates macrophage and dendritic cells to induce"/>
 <result pre="by the STAT1 signaling, it plays an important role in" exact="viral infection." post="Ning et al. (2019) used enzyme-linked immunosorbent assays to"/>
 <result pre="al. (2019) used enzyme-linked immunosorbent assays to demonstrate that SFTSV" exact="infection" post="caused a substantial production of serum IFN-γ in patients"/>
 <result pre="mouse model, which showed that IFN-γ treatment prior to SFTSV" exact="infection" post="significantly reduced mortality, protecting ~25% of animals from death,"/>
 <result pre="that ribavirin is effective for early-stage patients with a low" exact="viral" post="titer or for the pretreatment of exposed individuals. Nevertheless,"/>
 <result pre="of the possible adverse events induced by ribavirin such as" exact="anemia" post="and hyperamylasemia (Lu et al., 2015). Favipiravir exhibited higher"/>
 <result pre="Meanwhile, favipiravir remained effective when it was used following SFTSV" exact="infection" post="in animal models (Tani et al., 2016, 2018; Gowen"/>
 <result pre="drug library (Yuan et al., 2019). Because hexachlorophene can cause" exact="acute" post="and subacute neurotoxicity in laboratory animals and humans (Kimbrough,"/>
 <result pre="(Yuan et al., 2019). Because hexachlorophene can cause acute and" exact="subacute" post="neurotoxicity in laboratory animals and humans (Kimbrough, 1973; Ramu"/>
 <result pre="et al., 2019). Because hexachlorophene can cause acute and subacute" exact="neurotoxicity" post="in laboratory animals and humans (Kimbrough, 1973; Ramu et"/>
 <result pre="studies must be conducted. CCBs, which are used to control" exact="cardiovascular" post="diseases, have demonstrated significant effects against SFTSV replication both"/>
 <result pre="al., 2019). Although nifedipine is administrated consistently for patients with" exact="cardiac disease," post="these findings are valuable for developing potential CCB-based therapeutics"/>
 <result pre="action, but it was considered that CA interacts with the" exact="viral" post="particles, showing inhibitory effects (Ogawa et al., 2018). Because"/>
 <result pre="showing inhibitory effects (Ogawa et al., 2018). Because there are" exact="limited" post="reports regarding antiviral effects of CA or chlorogenic acid"/>
 <result pre="a critical role in the treating a wide variety of" exact="viral" post="diseases; such as acquired immunodeficiency syndrome (Ferrari et al.,"/>
 <result pre="the treating a wide variety of viral diseases; such as" exact="acquired" post="immunodeficiency syndrome (Ferrari et al., 2016), diseases caused by"/>
 <result pre="treating a wide variety of viral diseases; such as acquired" exact="immunodeficiency" post="syndrome (Ferrari et al., 2016), diseases caused by ebola"/>
 <result pre="a wide variety of viral diseases; such as acquired immunodeficiency" exact="syndrome" post="(Ferrari et al., 2016), diseases caused by ebola virus"/>
 <result pre="(Mendoza et al., 2017) and influenza (Nachbagauer and Krammer, 2017)." exact="Antibody" post="drugs neutralize viruses or bind to the virion to"/>
 <result pre="patient recovered from SFTS completely protected mice from the lethal" exact="infection" post="of SFTSV (Shimada et al., 2015). It was also"/>
 <result pre="SFTS. There are two studies for developing vaccines against SFTSV" exact="infection" post="(Dong et al., 2019; Kwak et al., 2019). A"/>
 <result pre="et al., 2019; Kwak et al., 2019). A recombinant vesicular" exact="stomatitis" post="virus expressing SFTSV antigen completely protected mice from SFTSV"/>
 <result pre="stomatitis virus expressing SFTSV antigen completely protected mice from SFTSV" exact="infection" post="(Dong et al., 2019). A DNA vaccine expressing antigens"/>
 <result pre="T cell response and protected aged-ferrets from the lethal SFTSV" exact="infection" post="(Kwak et al., 2019). Safe and effective vaccines against"/>
 <result pre="of being infected with SFTSV. SFTS is classified in a" exact="disease" post="category of viral hemorrhagic fever with high case fatality"/>
 <result pre="with SFTSV. SFTS is classified in a disease category of" exact="viral" post="hemorrhagic fever with high case fatality rate. Recently, cases"/>
 <result pre="The authors declare that the research was conducted in the" exact="absence of" post="any commercial or financial relationships that could be construed"/>
 <result pre="Dr. Masaaki Satoh, Department of Virology 1, National Institute of" exact="Infectious" post="Diseases, Tokyo, Japan. The present affiliate of Dr. Hideki"/>
 <result pre="an antiviral assay system and identification of severe fever with" exact="thrombocytopenia" post="syndrome virus inhibitors. Antivir. Chem. Chemother.25, 83–89. 10.1177/204020661774030329096526 BajramovicJ."/>
 <result pre="antiviral assay system and identification of severe fever with thrombocytopenia" exact="syndrome" post="virus inhibitors. Antivir. Chem. Chemother.25, 83–89. 10.1177/204020661774030329096526 BajramovicJ. J.VolmerR.SyanS.PochetS.Gonzalez-DuniaD."/>
 <result pre="Antivir. Chem. Chemother.25, 83–89. 10.1177/204020661774030329096526 BajramovicJ. J.VolmerR.SyanS.PochetS.Gonzalez-DuniaD. (2004). 2'-fluoro-2'-deoxycytidine inhibits" exact="Borna disease" post="virus replication and spread. Antimicrob. Agents Chemother.48, 1422–1425. 10.1128/AAC.48.4.1422-1425.200415047559"/>
 <result pre="Chem. Chemother.25, 83–89. 10.1177/204020661774030329096526 BajramovicJ. J.VolmerR.SyanS.PochetS.Gonzalez-DuniaD. (2004). 2'-fluoro-2'-deoxycytidine inhibits Borna" exact="disease" post="virus replication and spread. Antimicrob. Agents Chemother.48, 1422–1425. 10.1128/AAC.48.4.1422-1425.200415047559"/>
 <result pre="K.PadmanabhanR. (2017). Antiviral activities of selected antimalarials against dengue virus" exact="type 2" post="and Zika virus. Antiviral Res.137, 141–15010.1016/j.antiviral.2016.11.01527889529 BeaucourtS.VignuzziM. (2014). Ribavirin:"/>
 <result pre="BoonyasuppayakornS.ReichertE. D.ManzanoM.NagarajanK.PadmanabhanR. (2014). Amodiaquine, an antimalarial drug, inhibits dengue virus" exact="type 2" post="replication and infectivity. Antiviral Res.106, 125–134. 10.1016/j.antiviral.2014.03.01424680954 BułdakR. J.HejmoT.OsowskiM.BułdakŁ.KuklaM.PolaniakR.et"/>
 <result pre="its selected bioactive compounds on the development and progression of" exact="colorectal cancer" post="in vivo and in vitro. Molecules23:E3309. 10.3390/molecules2312330930551667 ChenX. P.CongM."/>
 <result pre="selected bioactive compounds on the development and progression of colorectal" exact="cancer" post="in vivo and in vitro. Molecules23:E3309. 10.3390/molecules2312330930551667 ChenX. P.CongM."/>
 <result pre="Molecules23:E3309. 10.3390/molecules2312330930551667 ChenX. P.CongM. L.LiM. H.KangY. J.FengY. M.PlyusninA.et al.. (2012)." exact="Infection" post="and pathogenesis of Huaiyangshan virus (a novel tick-borne bunyavirus)"/>
 <result pre="al.. (2012). Infection and pathogenesis of Huaiyangshan virus (a novel" exact="tick-borne" post="bunyavirus) in laboratory rodents. J. Gen. Virol.93, 1288–1293. 10.1099/vir.0.041053-022357748"/>
 <result pre="10.1099/vir.0.041053-022357748 ChoiS. J.ParkS. W.BaeI. G.KimS. H.RyuS. Y.KimH. A.et al.. (2016)." exact="Severe" post="fever with thrombocytopenia syndrome in South Korea, 2013-2015. PLoS"/>
 <result pre="W.BaeI. G.KimS. H.RyuS. Y.KimH. A.et al.. (2016). Severe fever with" exact="thrombocytopenia" post="syndrome in South Korea, 2013-2015. PLoS Negl. Trop. Dis.10:e0005264."/>
 <result pre="G.KimS. H.RyuS. Y.KimH. A.et al.. (2016). Severe fever with thrombocytopenia" exact="syndrome" post="in South Korea, 2013-2015. PLoS Negl. Trop. Dis.10:e0005264. 10.1371/journal.pntd.000526428033338"/>
 <result pre="10.1002/(SICI)1097-0010(19990301)79:3&amp;lt;362::AID-JSFA256&amp;gt;3.0.CO;2-D CyranoskiD. (2018). East Asia braces for surge in deadly" exact="tick-borne" post="virus news. Nature556, 282–283. 10.1038/d41586-018-04486-629666487 De ClercqE.LiG. (2016). Approved"/>
 <result pre="Rev.29, 695–747. 10.1128/CMR.00102-1527281742 DelangL.GuerreroN. S.TasA.QuératG.PastorinoB.FroeyenM.et al.. (2014). Mutations in the" exact="chikungunya" post="virus non-structural proteins cause resistance to favipiravir (T-705), a"/>
 <result pre="DongF.LiD.WenD.LiS.ZhaoC.QiY.et al.. (2019). Single dose of a rVSV-based vaccine elicits" exact="complete" post="protection against severe fever with thrombocytopenia syndrome virus. NPJ"/>
 <result pre="a rVSV-based vaccine elicits complete protection against severe fever with" exact="thrombocytopenia" post="syndrome virus. NPJ Vaccines4:5. 10.1038/s41541-018-0096-y30701094 FerrariG.HaynesB. F.KoenigS.NordstromJ. L.MargolisD. M.TomarasG."/>
 <result pre="rVSV-based vaccine elicits complete protection against severe fever with thrombocytopenia" exact="syndrome" post="virus. NPJ Vaccines4:5. 10.1038/s41541-018-0096-y30701094 FerrariG.HaynesB. F.KoenigS.NordstromJ. L.MargolisD. M.TomarasG. D."/>
 <result pre="(2016). Envelope-specific antibodies and antibody-derived molecules for treating and curing" exact="HIV infection." post="Nat. Rev. Drug Discov.15, 823–834. 10.1038/nrd.2016.17327725635 FurutaY.TakahashiK.ShirakiK.SakamotoK.SmeeD. F.BarnardD. L.et"/>
 <result pre="T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA" exact="viral" post="infections. Antiviral Res.82, 95–102. 10.1016/j.antiviral.2009.02.19819428599 GaiZ.LiangM.ZhangY.ZhangS.JinC.WangS. W.et al.. (2012)."/>
 <result pre="GaiZ.LiangM.ZhangY.ZhangS.JinC.WangS. W.et al.. (2012). Person-to-person transmission of severe fever with" exact="thrombocytopenia" post="syndrome bunyavirus through blood contact. Clin. Infect. Dis.54, 249–252."/>
 <result pre="W.et al.. (2012). Person-to-person transmission of severe fever with thrombocytopenia" exact="syndrome" post="bunyavirus through blood contact. Clin. Infect. Dis.54, 249–252. 10.1093/cid/cir77622095565"/>
 <result pre="Natl. Acad. Sci. U.S.A.115, 11613–11618. 10.1073/pnas.181134511530352857 GowenB. B.HickersonB. T. (2017)." exact="Hemorrhagic" post="fever of bunyavirus etiology: disease models and progress towards"/>
 <result pre="10.1073/pnas.181134511530352857 GowenB. B.HickersonB. T. (2017). Hemorrhagic fever of bunyavirus etiology:" exact="disease" post="models and progress towards new therapies. J. Microbiol.55, 183–195."/>
 <result pre="WettereA. J.RigasJ. D.HickersonB. T.et al.. (2017). Modeling severe fever with" exact="thrombocytopenia" post="syndrome virus infection in golden syrian hamsters: importance of"/>
 <result pre="J.RigasJ. D.HickersonB. T.et al.. (2017). Modeling severe fever with thrombocytopenia" exact="syndrome" post="virus infection in golden syrian hamsters: importance of STAT2"/>
 <result pre="D.HickersonB. T.et al.. (2017). Modeling severe fever with thrombocytopenia syndrome" exact="virus infection" post="in golden syrian hamsters: importance of STAT2 in preventing"/>
 <result pre="T.et al.. (2017). Modeling severe fever with thrombocytopenia syndrome virus" exact="infection" post="in golden syrian hamsters: importance of STAT2 in preventing"/>
 <result pre="infection in golden syrian hamsters: importance of STAT2 in preventing" exact="disease" post="and effective treatment with favipiravir. J. Virol.91, e01942–e01916. 10.1128/JVI.01942-1627881648"/>
 <result pre="of SARS-CoV. FEBS Lett.574, 116–120. 10.1016/j.febslet.2004.08.01515358550 JinC.JiangH.LiangM.HanY.GuW.ZhangF.et al.. (2015). SFTS" exact="virus infection" post="in nonhuman primates. J. Infect. Dis.211, 915–925. 10.1093/infdis/jiu56425326554 JinC.LiangM.NingJ.GuW.JiangH.WuW.et"/>
 <result pre="SARS-CoV. FEBS Lett.574, 116–120. 10.1016/j.febslet.2004.08.01515358550 JinC.JiangH.LiangM.HanY.GuW.ZhangF.et al.. (2015). SFTS virus" exact="infection" post="in nonhuman primates. J. Infect. Dis.211, 915–925. 10.1093/infdis/jiu56425326554 JinC.LiangM.NingJ.GuW.JiangH.WuW.et"/>
 <result pre="10.1093/infdis/jiu56425326554 JinC.LiangM.NingJ.GuW.JiangH.WuW.et al.. (2012). Pathogenesis of emerging severe fever with" exact="thrombocytopenia" post="syndrome virus in C57/BL6 mouse model. Proc. Natl. Acad."/>
 <result pre="JinC.LiangM.NingJ.GuW.JiangH.WuW.et al.. (2012). Pathogenesis of emerging severe fever with thrombocytopenia" exact="syndrome" post="virus in C57/BL6 mouse model. Proc. Natl. Acad. Sci."/>
 <result pre="al.. (2016). Epidemiological and clinical features of severe fever with" exact="thrombocytopenia" post="syndrome in Japan, 2013-2014. PLoS ONE11:e0165207. 10.1371/journal.pone.016520727776187 KidaK.MatsuokaY.ShimodaT.MatsuokaH.YamadaH.SaitoT.et al.."/>
 <result pre="(2016). Epidemiological and clinical features of severe fever with thrombocytopenia" exact="syndrome" post="in Japan, 2013-2014. PLoS ONE11:e0165207. 10.1371/journal.pone.016520727776187 KidaK.MatsuokaY.ShimodaT.MatsuokaH.YamadaH.SaitoT.et al.. (2019)."/>
 <result pre="(2019). A case of cat-to-human transmission of severe fever with" exact="thrombocytopenia" post="syndrome virus. Jpn. J. Infect. Dis.72, 356–358. 10.7883/yoken.JJID.2018.52631366857 KimK."/>
 <result pre="A case of cat-to-human transmission of severe fever with thrombocytopenia" exact="syndrome" post="virus. Jpn. J. Infect. Dis.72, 356–358. 10.7883/yoken.JJID.2018.52631366857 KimK. H.KimJ.KoM.ChunJ."/>
 <result pre="anti-Gn glycoprotein antibody from a convalescent patient potently inhibits the" exact="infection" post="of severe fever with thrombocytopenia syndrome virus. PLoS Pathog.15:e1007375."/>
 <result pre="convalescent patient potently inhibits the infection of severe fever with" exact="thrombocytopenia" post="syndrome virus. PLoS Pathog.15:e1007375. 10.1371/journal.ppat.100737530707748 KimK. H.YiJ.KimG.ChoiS. J.JunK. I.KimN."/>
 <result pre="patient potently inhibits the infection of severe fever with thrombocytopenia" exact="syndrome" post="virus. PLoS Pathog.15:e1007375. 10.1371/journal.ppat.100737530707748 KimK. H.YiJ.KimG.ChoiS. J.JunK. I.KimN. H.et"/>
 <result pre="PLoS Pathog.15:e1007375. 10.1371/journal.ppat.100737530707748 KimK. H.YiJ.KimG.ChoiS. J.JunK. I.KimN. H.et al.. (2013)." exact="Severe" post="fever with thrombocytopenia syndrome, South Korea, 2012. Emerg. Infect."/>
 <result pre="KimK. H.YiJ.KimG.ChoiS. J.JunK. I.KimN. H.et al.. (2013). Severe fever with" exact="thrombocytopenia" post="syndrome, South Korea, 2012. Emerg. Infect. Dis.19, 1892–189410.3201/eid1911.13079224206586 KimbroughR."/>
 <result pre="and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic" exact="avian influenza" post="H5N1, seasonal, and pandemic H1N1 virus infections. Antiviral Res.92,"/>
 <result pre="al.. (2019). Development of a SFTSV DNA vaccine that confers" exact="complete" post="protection against lethal infection in ferrets. Nat. Commun. 10,"/>
 <result pre="a SFTSV DNA vaccine that confers complete protection against lethal" exact="infection" post="in ferrets. Nat. Commun. 10, 1–11. 10.1038/s41467-019-11815-430602773 LanglandJ.JacobsB.WagnerC. E.RuizG.CahillT."/>
 <result pre="of metal chelates of caffeic acid and similar compounds towards" exact="herpes" post="simplex, VSV-Ebola pseudotyped and vaccinia viruses. Antiviral Res.160, 143–150."/>
 <result pre="acid and similar compounds towards herpes simplex, VSV-Ebola pseudotyped and" exact="vaccinia" post="viruses. Antiviral Res.160, 143–150. 10.1016/j.antiviral.2018.10.02130393014 LavanyaM.CuevasC. D.ThomasM.CherryS.RossS. R. (2013)."/>
 <result pre="In vitro antiviral activity of ribavirin against severe fever with" exact="thrombocytopenia" post="syndrome virus. Korean J. Intern. Med.32, 731–737. 10.3904/kjim.2016.10927899013 LiH.LuQ.BinX."/>
 <result pre="vitro antiviral activity of ribavirin against severe fever with thrombocytopenia" exact="syndrome" post="virus. Korean J. Intern. Med.32, 731–737. 10.3904/kjim.2016.10927899013 LiH.LuQ.BinX. B.ZhangS."/>
 <result pre="(2018). Epidemiological and clinical features of laboratory-diagnosed severe fever with" exact="thrombocytopenia" post="syndrome in China, 2011–17: a prospective observational study. Lancet"/>
 <result pre="Epidemiological and clinical features of laboratory-diagnosed severe fever with thrombocytopenia" exact="syndrome" post="in China, 2011–17: a prospective observational study. Lancet Infect."/>
 <result pre="L.et al.. (2019). Calcium channel blockers reduce severe fever with" exact="thrombocytopenia" post="syndrome virus (SFTSV) related fatality. Cell Res.29, 739–753. 10.1038/s41422-019-0214-z31444469"/>
 <result pre="al.. (2019). Calcium channel blockers reduce severe fever with thrombocytopenia" exact="syndrome" post="virus (SFTSV) related fatality. Cell Res.29, 739–753. 10.1038/s41422-019-0214-z31444469 LiuW.LuQ."/>
 <result pre="among hospitalized patients in china who had severe fever with" exact="thrombocytopenia" post="syndrome. Clin. Infect. Dis.57, 1292–1299. 10.1093/cid/cit53023965284 LiuY.WuB.PaesslerS.WalkerD. H.TeshR. B.YuX."/>
 <result pre="H.TeshR. B.YuX. J. (2014). The pathogenesis of severe fever with" exact="thrombocytopenia" post="syndrome virus infection in alpha/beta interferon knockout mice: insights"/>
 <result pre="B.YuX. J. (2014). The pathogenesis of severe fever with thrombocytopenia" exact="syndrome" post="virus infection in alpha/beta interferon knockout mice: insights into"/>
 <result pre="J. (2014). The pathogenesis of severe fever with thrombocytopenia syndrome" exact="virus infection" post="in alpha/beta interferon knockout mice: insights into the pathologic"/>
 <result pre="(2014). The pathogenesis of severe fever with thrombocytopenia syndrome virus" exact="infection" post="in alpha/beta interferon knockout mice: insights into the pathologic"/>
 <result pre="knockout mice: insights into the pathologic mechanisms of a new" exact="viral" post="hemorrhagic fever. J. Virol.88, 1781–1786. 10.1128/JVI.02277-1324257618 LuQ. B.ZhangS. Y.CuiN.HuJ."/>
 <result pre="al.. (2015). Common adverse events associated with ribavirin therapy for" exact="Severe" post="fever with thrombocytopenia syndrome. Antiviral Res.119, 19–22. 10.1016/j.antiviral.2015.04.00625892251 MendozaE."/>
 <result pre="adverse events associated with ribavirin therapy for Severe fever with" exact="thrombocytopenia" post="syndrome. Antiviral Res.119, 19–22. 10.1016/j.antiviral.2015.04.00625892251 MendozaE. J.RacineT.KobingerG. P. (2017)."/>
 <result pre="P. (2017). The ongoing evolution of antibody-based treatments for Ebola" exact="virus infection." post="Immunotherapy. 9, 435–450. 10.2217/imt-2017-001028357917 collab: Ministry of Health and"/>
 <result pre="(2011). Guideline for prevention and treatment of severe fever with" exact="thrombocytopenia" post="syndrome (2010 version). Chinese J. Clin. Infect. Dis.4, 193−194."/>
 <result pre="Guideline for prevention and treatment of severe fever with thrombocytopenia" exact="syndrome" post="(2010 version). Chinese J. Clin. Infect. Dis.4, 193−194. NachbagauerR.KrammerF."/>
 <result pre="10.1016/j.cmi.2017.02.00928216325 NakamuraS.AzumaM.MaruhashiT.SogabeK.SumitaniR.UemuraM.et al.. (2018). Steroid pulse therapy in patients with" exact="encephalopathy" post="associated with severe fever with thrombocytopenia syndrome. J. Infect."/>
 <result pre="therapy in patients with encephalopathy associated with severe fever with" exact="thrombocytopenia" post="syndrome. J. Infect. Chemother.24, 389–392. 10.1016/j.jiac.2017.11.00429428565 NingY.MoQ.FengK.MinY. Q.LiM.HouD.et al.."/>
 <result pre="al.. (2019). Interferon-γ-directed inhibition of a novel high-pathogenic phlebovirus and" exact="viral" post="antagonism of the antiviral signaling by targeting STAT1. Front."/>
 <result pre="signaling by targeting STAT1. Front. Immunol.10:1182. 10.3389/fimmu.2019.0118231191546 NiuG.LiJ.LiangM.JiangX.JiangM.YinH.et al.. (2013)." exact="Severe" post="fever with thrombocytopenia syndrome virus among domesticated animals, China."/>
 <result pre="STAT1. Front. Immunol.10:1182. 10.3389/fimmu.2019.0118231191546 NiuG.LiJ.LiangM.JiangX.JiangM.YinH.et al.. (2013). Severe fever with" exact="thrombocytopenia" post="syndrome virus among domesticated animals, China. Emerg. Infect. Dis.19,"/>
 <result pre="Front. Immunol.10:1182. 10.3389/fimmu.2019.0118231191546 NiuG.LiJ.LiangM.JiangX.JiangM.YinH.et al.. (2013). Severe fever with thrombocytopenia" exact="syndrome" post="virus among domesticated animals, China. Emerg. Infect. Dis.19, 756–763."/>
 <result pre="10.3201/eid1905.12024523648209 OgawaM.ShirasagoY.AndoS.ShimojimaM.SaijoM.FukasawaM. (2018). Caffeic acid, a coffee-related organic acid, inhibits" exact="infection" post="by severe fever with thrombocytopenia syndrome virus in vitro."/>
 <result pre="a coffee-related organic acid, inhibits infection by severe fever with" exact="thrombocytopenia" post="syndrome virus in vitro. J. Infect. Chemother.24, 597–601. 10.1016/j.jiac.2018.03.00529628386"/>
 <result pre="coffee-related organic acid, inhibits infection by severe fever with thrombocytopenia" exact="syndrome" post="virus in vitro. J. Infect. Chemother.24, 597–601. 10.1016/j.jiac.2018.03.00529628386 OhW."/>
 <result pre="Plasma exchange and ribavirin for rapidly progressive severe fever with" exact="thrombocytopenia" post="syndrome. Int. J. Infect. Dis.18, 84–86. 10.1016/j.ijid.2013.08.01124161209 RamuJ.KonakT.PauleM. G.HanigJ."/>
 <result pre="Neurotoxicology56, 225–232. 10.1016/j.neuro.2016.08.01127555423 SaijoM. (2018). Pathophysiology of severe fever with" exact="thrombocytopenia" post="syndrome and development of specific antiviral therapy. J. Infect."/>
 <result pre="225–232. 10.1016/j.neuro.2016.08.01127555423 SaijoM. (2018). Pathophysiology of severe fever with thrombocytopenia" exact="syndrome" post="and development of specific antiviral therapy. J. Infect. Chemother.24,"/>
 <result pre="Ebola virus host cell entry and are drug targets for" exact="disease" post="treatment. Science. 347, 995–998. 10.1126/science.125875825722412 SakuraiY.SakakibaraN.ToyamaM.BabaM.DaveyR. A. (2018). Novel"/>
 <result pre="10.1126/science.125875825722412 SakuraiY.SakakibaraN.ToyamaM.BabaM.DaveyR. A. (2018). Novel amodiaquine derivatives potently inhibit Ebola" exact="virus infection." post="Antiviral Res.160, 175–182. 10.1016/j.antiviral.2018.10.02530395872 ScherbikS. V.BrintonM. A. (2010). Virus-induced"/>
 <result pre="effect of post-exposure treatment with antiserum on severe fever with" exact="thrombocytopenia" post="syndrome (SFTS) in a mouse model of SFTS virus"/>
 <result pre="of post-exposure treatment with antiserum on severe fever with thrombocytopenia" exact="syndrome" post="(SFTS) in a mouse model of SFTS virus infection."/>
 <result pre="with thrombocytopenia syndrome (SFTS) in a mouse model of SFTS" exact="virus infection." post="Virology482, 19–27. 10.1016/j.virol.2015.03.01025817401 ShimojimaM.FukushiS.TaniH.TaniguchiS.FukumaA.SaijoM. (2015). Combination effects of ribavirin"/>
 <result pre="Combination effects of ribavirin and interferons on severe fever with" exact="thrombocytopenia" post="syndrome virus infection. Virol. J.12:181. 10.1186/s12985-015-0412-326527529 ShimojimaM.FukushiS.TaniH.YoshikawaT.FukumaA.TaniguchiS.et al.. (2014)."/>
 <result pre="effects of ribavirin and interferons on severe fever with thrombocytopenia" exact="syndrome" post="virus infection. Virol. J.12:181. 10.1186/s12985-015-0412-326527529 ShimojimaM.FukushiS.TaniH.YoshikawaT.FukumaA.TaniguchiS.et al.. (2014). Effects"/>
 <result pre="of ribavirin and interferons on severe fever with thrombocytopenia syndrome" exact="virus infection." post="Virol. J.12:181. 10.1186/s12985-015-0412-326527529 ShimojimaM.FukushiS.TaniH.YoshikawaT.FukumaA.TaniguchiS.et al.. (2014). Effects of ribavirin"/>
 <result pre="ShimojimaM.FukushiS.TaniH.YoshikawaT.FukumaA.TaniguchiS.et al.. (2014). Effects of ribavirin on severe fever with" exact="thrombocytopenia" post="syndrome virus in vitro. Jpn. J. Infect. Dis.67, 423–427."/>
 <result pre="al.. (2014). Effects of ribavirin on severe fever with thrombocytopenia" exact="syndrome" post="virus in vitro. Jpn. J. Infect. Dis.67, 423–427. 10.7883/yoken.67.42325410555"/>
 <result pre="a broad-spectrum inhibitor of bunyaviruses in vitro and in phleboviral" exact="disease" post="mouse models. Antiviral Res.160, 48–54. 10.1016/j.antiviral.2018.10.01330339848 SnellN. J. (2001)."/>
 <result pre="10.1517/14656566.2.8.131711585000 SpenglerJ. R.BenteD. A.BrayM.BurtF.HewsonR.KorukluogluG.et al.. (2018). Second international conference on" exact="Crimean-Congo hemorrhagic fever." post="Antiviral Res.150, 137–147. 10.1016/j.antiviral.2017.11.01929199036 TakahashiT.MaedaK.SuzukiT.IshidoA.ShigeokaT.TominagaT.et al.. (2014). The first"/>
 <result pre="The first identification and retrospective study of severe fever with" exact="thrombocytopenia" post="syndrome in Japan. J. Infect. Dis.209, 816–827. 10.1093/infdis/jit60324231186 TangH.YaoX.YaoC.ZhaoX.ZuoH.LiZ."/>
 <result pre="first identification and retrospective study of severe fever with thrombocytopenia" exact="syndrome" post="in Japan. J. Infect. Dis.209, 816–827. 10.1093/infdis/jit60324231186 TangH.YaoX.YaoC.ZhaoX.ZuoH.LiZ. (2017)."/>
 <result pre="in Japan. J. Infect. Dis.209, 816–827. 10.1093/infdis/jit60324231186 TangH.YaoX.YaoC.ZhaoX.ZuoH.LiZ. (2017). Anti-colon" exact="cancer" post="effect of caffeic acid p-nitro-phenethyl ester in vitro and"/>
 <result pre="al.. (2016). Efficacy of T-705 (Favipiravir) in the treatment of" exact="infections" post="with lethal severe fever with thrombocytopenia syndrome virus. mSphere1,"/>
 <result pre="in the treatment of infections with lethal severe fever with" exact="thrombocytopenia" post="syndrome virus. mSphere1, e00061–e00015. 10.1128/mSphere.00061-1527303697 TaniH.KomenoT.FukumaA.FukushiS.TaniguchiS.ShimojimaM.et al.. (2018). Therapeutic"/>
 <result pre="the treatment of infections with lethal severe fever with thrombocytopenia" exact="syndrome" post="virus. mSphere1, e00061–e00015. 10.1128/mSphere.00061-1527303697 TaniH.KomenoT.FukumaA.FukushiS.TaniguchiS.ShimojimaM.et al.. (2018). Therapeutic effects"/>
 <result pre="al.. (2018). Therapeutic effects of favipiravir against severe fever with" exact="thrombocytopenia" post="syndrome virus infection in a lethal mouse model: dose-efficacy"/>
 <result pre="(2018). Therapeutic effects of favipiravir against severe fever with thrombocytopenia" exact="syndrome" post="virus infection in a lethal mouse model: dose-efficacy studies"/>
 <result pre="Therapeutic effects of favipiravir against severe fever with thrombocytopenia syndrome" exact="virus infection" post="in a lethal mouse model: dose-efficacy studies upon oral"/>
 <result pre="effects of favipiravir against severe fever with thrombocytopenia syndrome virus" exact="infection" post="in a lethal mouse model: dose-efficacy studies upon oral"/>
 <result pre="(2005). Sources of interferon-gamma (IFN-γ) in early immune response to" exact="Listeria" post="monocytogenes. Immunobiology210, 673–683. 10.1016/j.imbio.2005.07.00316323704 TranX. C.YunY.AnLVan KimS. H.ThaoN. T."/>
 <result pre="T. P.ManP. K. C.et al.. (2019). Endemic severe fever with" exact="thrombocytopenia" post="syndrome, Vietnam. Emerg. Infect. Dis.25, 1029–1031. 10.3201/eid2505.18146331002059 UtsunomiyaH.IchinoseM.IkedaK.UozakiM.MorishitaJ.KuwaharaT.et al.."/>
 <result pre="WangS.LiuY.GuoJ.WangP.ZhangL.XiaoG.et al.. (2017). Screening of FDA-approved drugs for inhibitors of" exact="Japanese encephalitis" post="virus infection. J. Virol.91, e01055–e01017. 10.1128/JVI.01055-1728814523 WelchS. R.GuerreroL. W.ChakrabartiA."/>
 <result pre="al.. (2017). Screening of FDA-approved drugs for inhibitors of Japanese" exact="encephalitis" post="virus infection. J. Virol.91, e01055–e01017. 10.1128/JVI.01055-1728814523 WelchS. R.GuerreroL. W.ChakrabartiA."/>
 <result pre="(2017). Screening of FDA-approved drugs for inhibitors of Japanese encephalitis" exact="virus infection." post="J. Virol.91, e01055–e01017. 10.1128/JVI.01055-1728814523 WelchS. R.GuerreroL. W.ChakrabartiA. K.McMullanL. K.FlintM.BluemlingG."/>
 <result pre="al.. (2017). Identification of 2′-deoxy-2′-fluorocytidine as a potent inhibitor of" exact="Crimean-Congo hemorrhagic fever" post="virus replication using a recombinant fluorescent reporter virus. Antiviral"/>
 <result pre="91–99. 10.1016/j.antiviral.2017.10.00829024765 WohlrabF.JamiesonA. T.HayJ.MengelR.GuschlbauerW. (1985). The effect of 2′-fluoro-2′-deoxycytidine on" exact="herpes" post="virus growth. Biochim. Biophys. Acta824, 233–242. 10.1016/0167-4781(85)90053-32982405 collab: World"/>
 <result pre="233–242. 10.1016/0167-4781(85)90053-32982405 collab: World Health Organization (2017). Annual Review of" exact="Diseases" post="Prioritized Under the Research and Development Blueprint, 2017. Available"/>
 <result pre="of therapeutic plasma exchange in patients having severe fever with" exact="thrombocytopenia" post="syndrome. Korean J. Intern. Med.34, 902–909. 10.3904/kjim.2016.19429117665 YoshikawaR.SakabeS.UrataS.YasudaJ. (2019)."/>
 <result pre="902–909. 10.3904/kjim.2016.19429117665 YoshikawaR.SakabeS.UrataS.YasudaJ. (2019). Species-specific pathogenicity of severe fever with" exact="thrombocytopenia" post="syndrome virus is determined by anti-STAT2 activity of NSs."/>
 <result pre="10.3904/kjim.2016.19429117665 YoshikawaR.SakabeS.UrataS.YasudaJ. (2019). Species-specific pathogenicity of severe fever with thrombocytopenia" exact="syndrome" post="virus is determined by anti-STAT2 activity of NSs. J."/>
 <result pre="e02226–e02218. 10.1128/JVI.02226-1830814285 YuX. J.LiangM. F.ZhangS. Y.LiuY.LiJ. D.SunY. L.et al.. (2011)." exact="Fever" post="with thrombocytopenia associated with a novel bunyavirus in China."/>
 <result pre="YuX. J.LiangM. F.ZhangS. Y.LiuY.LiJ. D.SunY. L.et al.. (2011). Fever with" exact="thrombocytopenia" post="associated with a novel bunyavirus in China. N. Engl."/>
 <result pre="two-tier system identifies an entry inhibitor of severe fever with" exact="thrombocytopenia" post="syndrome virus. Viruses11:E385. 10.3390/v1104038531027241 ZhuL.YinF.MomingA.ZhangJ.WangB.GaoL.et al.. (2019). First case"/>
 <result pre="system identifies an entry inhibitor of severe fever with thrombocytopenia" exact="syndrome" post="virus. Viruses11:E385. 10.3390/v1104038531027241 ZhuL.YinF.MomingA.ZhangJ.WangB.GaoL.et al.. (2019). First case of"/>
 <result pre="ZhuL.YinF.MomingA.ZhangJ.WangB.GaoL.et al.. (2019). First case of laboratory-confirmed severe fever with" exact="thrombocytopenia" post="syndrome disease revealed the risk of SFTSV infection in"/>
 <result pre="al.. (2019). First case of laboratory-confirmed severe fever with thrombocytopenia" exact="syndrome" post="disease revealed the risk of SFTSV infection in Xinjiang,"/>
 <result pre="(2019). First case of laboratory-confirmed severe fever with thrombocytopenia syndrome" exact="disease" post="revealed the risk of SFTSV infection in Xinjiang, China."/>
 <result pre="fever with thrombocytopenia syndrome disease revealed the risk of SFTSV" exact="infection" post="in Xinjiang, China. Emerg. Microbes Infect.8, 1122–1125. 10.1080/22221751.2019.164557331347462 ZivcecM.SafronetzD.FeldmannH."/>
 <result pre="Emerg. Microbes Infect.8, 1122–1125. 10.1080/22221751.2019.164557331347462 ZivcecM.SafronetzD.FeldmannH. (2013). Animal models of" exact="tick-borne" post="hemorrhagic fever viruses. Pathogens2, 402–421. 10.3390/pathogens202040225437041"/>
</results>
